CLIMARA (estradiol) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 1994.
Drug data last refreshed 9h ago · AI intelligence enriched 12h ago
CLIMARA is a transdermal extended-release film delivering estradiol, an estrogen receptor agonist approved in 1994 for hormone replacement therapy. It treats menopausal symptoms by restoring estrogen levels through skin absorption. The product uses a passive transdermal delivery system to provide sustained therapeutic exposure.
Mature product in declining phase with stable but modest market presence signals limited commercial expansion opportunities and smaller team footprint.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Worked on CLIMARA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLIMARA offers limited career advancement in a mature, crowded category with declining market dynamics; most roles focus on managed care negotiations, generic defense, and market retention. Career growth is constrained by flat-to-declining commercial trajectory and minimal innovation pipeline, making this role best suited for experienced professionals managing mature portfolios.